Cord Blood News Volume 11.41 | Oct 24 2019

TOP STORY

Stromal Cells from Perinatal and Adult Sources Modulate the Inflammatory Immune Response In Vitro by Decreasing Th1 Cell Proliferation and Cytokine Secretion

Researchers investigated the role of human stromal cells derived from the amniotic fluid, the placenta, and bone marrow-derived mesenchymal stromal cells in modulating the inflammatory response of in vitro-stimulated circulating blood-derived immune cells. [Stem Cells Transl Med] Full Article

(Ranked by impact factor of the journal)

Comparison of the Therapeutic Effect of Amniotic Fluid Stem Cells and Their Exosomes on Monoiodoacetate-Induced Animal Model of Osteoarthritis

Investigators explored the efficacy of the secreted exosomes, compared to their amniotic fluid stem cell source, in MIA-induced animal model of osteoarthritis mimicking a chronic and degenerative process, where inflammation was also involved and lead to irreversible joint damage. [BioFactors] Abstract

Epigenetic Regulation of Amniotic Fluid Mesenchymal Stem Cell Differentiation to the Mesodermal Lineages at Normal and Fetus-Diseased Gestation

The authors evaluated the efficacy of mesenchymal stem cells from amniotic fluid when pregnancy was normal or when the fetus was affected during pregnancy to differentiate into mesodermal lineage tissues and to elucidate epigenetic states responsible for terminal adipogenic and osteogenic differentiation. [J Cell Biochem] Abstract

Comparison of Calcineurin Inhibitors in Combination with Conventional Methotrexate, Reduced Methotrexate, or Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host Disease after Umbilical Cord Blood Transplantation

Researchers retrospectively compared outcomes in 409 patients who received calcineurin inhibitors (CIs) plus conventional-dose methotrexate with those who received CIs plus reduced-dose methotrexate or CIs with mycophenolate mofetil for graft-versus-host disease prophylaxis after umbilical cord blood transplantation. [Ann Hematol] Abstract

Cord Blood S100B: Reference Ranges and Interest for Early Identification of Newborns with Brain Injury

Scientists established S100B cord blood serum reference intervals from 183 preterm and 200 full-term neonates. They then measured cord blood serum S100B to identify neurological complications in 272 neonates hospitalized at the neonatal intensive care unit. [Clin Chem Lab Med] Abstract

Overcoming the Deceptively Low Viability of CD45⁺ Cells in Thawed Cord Blood Unit Segments

Investigators revealed that initiating staining at 20 min post-thaw instead of 30, shortening red cell lysis treatment, or performing lysis on ice and removing this step altogether, all improved the viability of CD45⁺ cells. [Vox Sang] Abstract

Subscribe to one of our other 19 science newsletters such as Hematopoiesis News & Cell Therapy News.

My Jamais Vu in Post Allogeneic Hematopoietic Cell Transplant: A Review on Secondary Hemophagocytosis in Adults

Post allogenic hematopoietic cell transplant (HCT) hemophagocytic lymphohistiocytosis (HLH) is an aggressive disease with unknown etiology. It usually occurs early in the first two to six weeks after allogeneic HCT but can present late. The incidence is highest among cord blood transplant compared with other sources of stem cells with a higher incidence in HLA mismatch donors. It has been recently found that etoposide based conditioning regimen may reduce HLH post HCT. [Bone Marrow Transplant] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

NYSCF Announces 2019 Class of NYSCF – Robertson Investigators

The New York Stem Cell Foundation (NYSCF) announced the 2019 class of NYSCF – Robertson Investigators, welcoming six of the most talented stem cell researchers and neuroscientists into the NYSCF Investigator Program. [New York Stem Cell Foundation (EurekaAlert)] Press Release

Female Researchers in Australia Less Likely to Win Major Medical Grants than Males

Female scientists in Australia were less likely to win a major type of medical-research grants this year than their male counterparts, despite an overhaul of the country’s science funding that was supposed to address gender inequity. [Nature News] Editorial

Trump Names Seven to Revived Presidential Science Advisory Panel

Thirty-three months after taking office, President Donald Trump has chosen a group of business leaders to advise him on science and technology policy. [ScienceInsider] Editorial

NEW 10^th International Meeting of the Stem Cell Network North Rhine-Westphalia
June 8-July 9, 2020
Aachen, Germany

Visit our events page to see a complete list of events in the community.

NEW Research Assistant – Stem Cells and Engineering (New York Blood Center)

Group Leader – Vascular Biology, Hematopoiesis or Cardiovascular Disease (University of Wurzburg)

Postdoctoral Fellow – Normal and Malignant Hematopoiesis (Versiti Blood Research Institute)

PhD Positions – Cancer and Developmental Biology (Peter MacCallum Cancer Centre)

Research Fellow – Iron-Altered Hematopoiesis (New York Blood Center)

Postdoctoral Research Fellow – Hematology, Blood Disorders and Stem Cell Biology (New York Blood Center)

Tenure-Track Faculty Position – Stem Cell Biology (Albert Einstein College of Medicine)

Faculty Position – Hematopoietic Biology and Malignancy (The University of Texas MD Anderson Cancer Center)

Postdoctoral Research Associate – Solid Tumors and Leukemia (St. Jude Children’s Research Hospital)

PhD Positions – Age-Related Changes in Hematopoiesis (University of Milano-Bicocca)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here.